Sponsors (4)
The bill removes certain method-of-use patent barriers and clarifies labeling/promotional rules to speed generic/biosimilar entry and reduce prices, but it weakens patent enforcement in ways that may reduce R&D incentives, raise safety and prescribing-complexity concerns, and create fairness issues from retroactive immunity.
Patients and payers: reducing method-of-use litigation risk lets generic and biosimilar makers enter the market and promote products using approved labeling, increasing competition and likely lowering drug prices.
Manufacturers and health systems: tying permitted promotional and labeling conduct to FDA definitions reduces regulatory uncertainty for sponsors and providers, making compliance easier and lowering legal/regulatory costs.
Sponsors and hospitals: retroactive application of the safe harbor can resolve past exposure uncertainty and clear pending litigation risk under the new rule, reducing ongoing legal liability.
Patients and future-drug beneficiaries: patent holders lose a legal tool to enforce method-of-use patents, which could reduce incentives for some targeted drug R&D and slow development of new indications.
Patients and health systems: manufacturers might omit patented indications from labeling while marketing broadly, increasing the risk of off-label use and complicating safe prescribing.
Hospitals, prescribers, and payers: the law could encourage strategic narrowing of labels to avoid patents rather than licensing, shifting costs and complexity to clinicians and payers who must navigate omitted indications.
Based on analysis of 2 sections of legislative text.
Introduced January 9, 2025 by John Wright Hickenlooper · Last progress January 9, 2025
Creates statutory safe harbors that protect generic-drug, animal-generic, certain 505(b)(2) applicants, and biosimilar applicants and sellers from direct, induced, or contributory patent-infringement claims when they use FDA-approved labeling that omits patented conditions of use and otherwise follow application and marketing rules. The protections apply to ANDA/animal generic/505(b)(2) filings and 351(k) biosimilar filings and marketing, are conditioned on not referencing the patented uses, and apply retroactively to conduct and proceedings before, on, or after enactment.